Volume 17, Issue 2

Volume 17, Issue 2
15June2022

Letter from the ECCO President

Laurent Peyrin-Biroulet, ECCO President


Laurent Peyrin-Biroulet
© ECCO

 

Dear ECCO Friends,

With the summer approaching we hope you enjoy the second Issue of ECCO NEWS where you will find the preliminary scientific programme and our educational Activities at ECCO’23. As usual we offer a wide range of Workshops and Courses for IBD Nurses, surgeons, young gastroenterologists, paediatricians, scientists and allied healthcare professionals.

Posted in ECCO News, Letters from the ECCO President, Volume 17, Issue 2

15June2022

ECCO Standpoint on JAK inhibitors in IBD

S. Danese, F. Magro, A. Hart, J. van der Woude, A. Armuzzi, B. Siegmund, L. Peyrin-Biroulet

In a recent randomized trial by Ytterberg and colleagues, called Oral Surveillance, patients with rheumatoid arthritis (RA) aged > 50 years and with at least an additional cardiovascular (CV) risk factor at baseline, treated with tofacitinib 5 or 10 mg twice daily experienced a higher proportion of major adverse cardiovascular events (MACE) and cancer compared with the control group (adalimumab or etanercept) [1]. 

These new data might have crucial implications in ulcerative colitis (UC) where tofacitinib, filgotinib and upadacitinib are approved.

Posted in ECCO News, Volume 17, Issue 2

15June2022

18th Congress of ECCO 2023 Copenhagen: Overview of Scientific and Educational Programmes

Alessandro Armuzzi, Brigida Barbeiro and Spyros Siakavellas, ECCO News Editor & Associate Editors

Alessandro Armuzzi
© Alessandro Armuzzi
Brigida Barberio
© Brigida Barberio
Spyros Siakavellas
© Spyros Siakavellas

Dear IBD colleagues and friends,

Warm greetings from the ECCO News Team at the beginning of this hopeful spring, following two very challenging years.

After two years of meeting each other virtually due to the COVID-19 pandemic, we are optimistic that next year we will return to face-to-face interaction at the 18th Congress of ECCO in the vibrant city of Copenhagen. At last, we will able to share and exchange knowledge and ideas in person and not from behind a screen!

Scientific sessions will be held from Thursday to Saturday, March 2–4, 2023, while the Educational Programme will start earlier in the week, on Wednesday, March 1, and will finish at the end of the morning of March 2 in order to allow for a seamless experience with no overlapping sessions and to cater for all delegates. We kindly ask you to take a careful look at the ECCO'23 Congress Website for further details.

Posted in ECCO News, ECCO'23, Congress News, Volume 17, Issue 2

15June2022

Call for abstracts for the 18th Congress of ECCO



To submit an abstract for the 18th Congress of ECCO, use our ECCO Portal.

Please also view important information on the submission process and the guidelines for abstract submission.

Posted in ECCO News, ECCO'23, Congress News, Volume 17, Issue 2

15June2022

Call for Participants: The 14th N-ECCO School


N-ECCO School
© ECCO

At the 18th Congress of ECCO in Copenhagen, the Nurses of ECCO (N-ECCO) will host the educational activity for IBD Nurses, N-ECCO School, for the 14th time. ECCO intends to give nurses, who might be still in training and have an interest in IBD, the possibility to attend an IBD-focused course. The ultimate aim of this programme is to improve nurse education throughout Europe.

Posted in ECCO News, ECCO'23, Congress News, Volume 17, Issue 2, N-ECCO

15June2022

Call for Participants: The 21st IBD Intensive Course for Trainees


IBD Intensive Course for Trainees
© ECCO

The 21st ECCO Intensive Course for Trainees designed for residents, fellows in gastroenterology and junior faculty will take place in Copenhagen, Denmark, on March 1, 2022, immediately prior to our next Congress. We are pleased to inform you that the preliminary programme for this course is already available.

Posted in ECCO News, ECCO'23, Congress News, EduCom, Volume 17, Issue 2

15June2022

ECCO Young Researcher Award

Sebastian Zeissig, SciCom Chair

Sebastian Zeissig 
© ECCO

Dear ECCO Friends and Members,

It is with great pleasure and excitement that we announce the brand new ECCO Young Researcher Award 2022. This new ECCO Prize will be awarded to outstanding young researchers in recognition of their excellent contributions to basic and clinical science in the field of IBD. With this prize, ECCO strives to further support the visibility of exceptional young talents in IBD, acknowledge their achievements in the field and facilitate their ongoing and future research.

Posted in ECCO News, Committee News, SciCom, Volume 17, Issue 2

15June2022

New SciCom member

Sebastian Zeissig, SciCom Chair and Isabelle Cleynen, SciCom Member

Sebastian Zeissig
© ECCO


Isabelle Cleynen
© ECCO

SciCom announces the recent election of new member Isabelle Cleynen during the ECCO’22 Congress, with a mandate running from 2022 to 2025.

Posted in ECCO News, Committee News, SciCom, Volume 17, Issue 2

15June2022

I-CARE: An imminent European success story in the field of IBD

Laurent Beaugerie, ClinCom Member


Laurent Beaugerie
© ECCO

The efficacy profile of IBD drugs is rapidly characterised by pivotal randomised controlled trials, but the safety profile of both old and new IBD drugs can only be established after years or decades of post-approval use. This is particularly true for relatively rare events, such as immunosuppression-related cancers. Clinical trials, meta-analyses and safety-dedicated registries are in general underpowered to evaluate the impact of IBD therapies on the risk of development of particular cancers. Data on clinical activity and phenotype of IBD are missing from nationwide administrative health databases, making it impossible to distinguish between the respective effects of IBD drugs and IBD activity on the risk of outcomes of particular interest, such as lymphomas.

Posted in ECCO News, Committee News, ClinCom, Volume 17, Issue 2

15June2022

Report from IIS Award Winner 2022: Edouard Louis

Edouard Louis, ECCO Member


Edouard Louis
© Edouard Louis

The SPARE clinical trial

A treat-to-target strategy and tight disease control may improve outcome in Crohn’s Disease (CD). However, this approach may necessitate long-term use of biological agents and immunosuppression. Combination therapy with anti-TNF and antimetabolite agents is now well established in this context. These drugs may be associated with long-term risks and elevated costs. It is important to establish whether treatment de-escalation, once deep remission has been achieved, is feasible and whether this strategy may improve safety profile and costs without jeopardising disease control.

Posted in ECCO News, Committee News, ClinCom, Volume 17, Issue 2, ECCO'22